Firefly Neuroscience and NeuroSigma Partner to Expand Non-Drug Pediatric ADHD Treatment Access

Firefly Neuroscience and NeuroSigma Join Forces on ADHD Treatment

Firefly Neuroscience Inc. (NASDAQ:AIFF), an artificial intelligence company advancing precision neuroscience, has partnered with NeuroSigma, Inc., a bioelectronic medical device firm, to expand clinician awareness and access to non-drug ADHD therapy across the United States1

1

2

2

. The collaboration will introduce NeuroSigma's Monarch eTNS System to psychiatry, neurology, and behavioral health practices utilizing Firefly's FDA-cleared AI-powered Evoke platform1

1

. This partnership directly addresses an unmet need in ADHD treatment, as families increasingly seek alternatives to traditional stimulant medications for their children.

Addressing Critical Gaps in Pediatric ADHD Care

The partnership tackles two pressing challenges in pediatric ADHD management by combining objective brain function insights with a medication-free treatment alternative. A 2024 study published in the Journal of Clinical Child & Adolescent Psychology revealed that approximately 7.1 million U.S. children have received an ADHD diagnosis, representing roughly one in nine children1

1

2

2

. Among the approximately 6.5 million children with current ADHD, nearly one-third receive no ADHD-specific treatment1

1

. This substantial treatment gap highlights the urgent need for accessible, non-pharmaceutical options that can serve families actively seeking alternatives to stimulant medications.

How the AI-Powered Evoke Platform and Monarch System Work Together

Firefly's Evoke platform combines quantitative electroencephalography and event-related potential testing with AI analytics, leveraging a proprietary database exceeding 200,000 brain scans to deliver objective data on individual brain function1

1

2

2

. In March 2026, Firefly identified EEG/ERP biomarkers using Evoke data that may help differentiate among the three ADHD presentations: predominantly inattentive, predominantly hyperactive-impulsive, and combined1

1

2

2

. This AI-driven diagnostics capability assists clinicians in treatment matching and tracking progress over time. NeuroSigma's prescription-only Monarch eTNS System is a palm-sized bioelectronic medical device that delivers mild external trigeminal nerve stimulation via a small forehead patch while a child sleeps1

1

2

2

. The FDA cleared the device as a monotherapy for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD drugs1

1

.

Commercial Rollout and Market Response

NeuroSigma launched U.S. sales for its second-generation Monarch device in July 2026 after building a waitlist of over 1,500 patients, caregivers, and healthcare providers1

1

. The company subsequently expanded third-party installment payment options in September, making the treatment more financially accessible to families1

1

2

2

. Under the partnership agreement, Firefly will introduce the Monarch eTNS System to its Evoke clinician network and support clinician education, while NeuroSigma will provide clinical training, prescribing support, and product fulfillment through its specialty pharmacy partner2

2

. AIFF stock responded positively to the announcement, with Firefly Neuroscience shares surging 42.01% to $1.68 at the time of publication1

1

. This market reaction suggests investor confidence in the partnership's potential to address the substantial unmet need in pediatric ADHD care while expanding both companies' reach within the clinician network treating these patients.